SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced a public offering of 10,000,000 shares of common stock at a price of $46.50 per share, resulting in estimated net proceeds to Amylin of approximately $441.4 million. The Company has granted to the underwriters an option to purchase up to 1,500,000 additional shares of common stock from the company to cover over-allotments, if any, within 30 days from the date of the prospectus supplement.
Morgan Stanley & Co. Incorporated is acting as the sole bookrunning and co-lead manager for the offering. Goldman, Sachs & Co. is acting as a co-lead manager of the offering. Co-managers for the offering are Bear, Stearns & Co. Inc. and Lehman Brothers Inc.
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.
Copies of the prospectus supplement may be obtained, when available, from the Prospectus Department of Morgan Stanley & Co. Incorporated (1585 Broadway, New York, New York 10036, phone 212-761-6775, fax 212-761-0211).
Amylin Pharmaceuticals, Inc.
CONTACT: Mark G. Foletta, Senior Vice President, Finance and ChiefFinancial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200
Web site: http://www.amylin.com//
